	US 12,319,702 B2
	Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
Vincent John Santora, San Diego, CA (US); Mi Chen, San Diego, CA (US); and DeMichael Chung, San Diego, CA (US)
Assigned to Dart NeuroScience, LLC, Dallas, TX (US)
Filed by Dart NeuroScience, LLC, Dallas, TX (US)
Filed on Jun. 15, 2023, as Appl. No. 18/210,382.
Application 18/210,382 is a continuation of application No. 16/629,922, granted, now 11,685,745, previously published as PCT/US2018/041565, filed on Jul. 11, 2018.
Claims priority of provisional application 62/531,802, filed on Jul. 12, 2017.
Prior Publication US 2024/0199643 A1, Jun. 20, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 498/10 (2006.01); C07D 519/00 (2006.01)

CPC C07D 498/10 (2013.01) [C07D 519/00 (2013.01)]

15 Claims

1. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier; and a compound of Formula (1), or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

5-chloro-2-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-ylmethyl]-7,8-dihydro-6H-spiro[[1,3]oxazolo[5,4-f]quinazoline-9,1′-cyclohexane]-7-one;

5-chloro-2-[(3-methoxy-3-methylazetidin-1-yl)methyl]-7,8-dihydro-6H-spiro [[1,3]oxazolo[5,4-f]quinazoline-9,1′-cyclohexane]-7-one;

5-chloro-2-{[3-(hydroxymethyl) pyrrolidin-1-yl]methyl}-7,8-dihydro-6H-spiro [[1,3]oxazolo[5,4-f]quinazoline-9,1′-cyclohexane]-7-one; and

5-chloro-2-({[2-(dimethylamino)ethyl](methyl)amino}methyl)-7,8-dihydro-6H-spiro [[1,3]oxazolo[5,4-f]quinazoline-9,1′-cyclohexane]-7-one.